Type 2 & other diabetes

Long‐term weight loss and cardiorenal outcomes by baseline body mass index (BMI) in the VERTIS cardiovascular (CV) trial

Diabetes Obes MetabPublished Secondary analysis of the VERTIS CV randomised trial

Authors' conclusion

Weight loss was observed across baseline BMI and was sustained over 5 years of follow-up. The effects of ertugliflozin on HHF and kidney composite were consistent across baseline BMI.

Study context

Population
Patients with T2D and atherosclerotic CVD; mean age 64.4 years, diabetes duration 13.0 years, BMI 32.0 kg/m², 61% with BMI >30 kg/m²
Participants
8,246 patients
Comparison
Ertugliflozin vs placebo by baseline BMI
Primary endpoint
Weight loss and cardiorenal outcomes (CV death or HHF composite, CV death, HHF, exploratory kidney composite incl. ≥40% eGFR decrease) by baseline BMI
Methodological detailspost hoc analysis, subgroups by baseline BMI
  • Post hoc analysis
  • Subgroups by baseline BMI

Primary result

As reported in the abstract

  • Absolute body weight reduction greater with ertugliflozin vs placebo at 3 and 5 years across BMI subgroups
  • No significant difference in effect of ertugliflozin on HHF across BMI subgroups
  • No significant difference in effect of ertugliflozin on kidney composite across BMI subgroups
  • Results similar for other CV outcomes
  • Ertugliflozin vs Placebo: P for interaction = 0.61
  • Ertugliflozin vs Placebo: P for interaction = 0.39

Further findings

OutcomeErtugliflozinPlaceboOR (95% CI)
≥5% body weight reduction · 5 years34.9%19.4%2.21 (1.76–2.77)
≥10% body weight reduction · 5 years13.6%4.1%3.65 (2.39–5.57)
Absolute body weight reduction, overall population · 3 and 5 years · greater reduction with ertugliflozin
P < 0.001

Safety

Safety consistent with the known ertugliflozin profile

Original publication

Long‐term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial. Diabetes Obes Metab. Published 18 December 2024. doi:10.1111/dom.16050

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.